For the treatment of bleeding episodes in people* with hemophilia A or B with inhibitors

HE’S READY TO MOVE ON

SEVENFACT

The first inhibitor bypassing agent approved in the US in over 20 years1,2
Differs molecularly from other available rFVIIa3

For the treatment of bleeding episodes in people* with hemophilia A or B with inhibitors

HE’S READY TO MOVE ON

SEVENFACT

The first inhibitor bypassing agent approved in the US in over 20 years1,2
Differs molecularly from the other available rFVIIa3

SEVENFACT Patient Videos

Learn how SEVENFACT has helped make patients' lives more predictable.

Living with an inhibitor
is unpredictable4-7

Controlling bleeds quickly is of critical concern

Rapid, predictable, and reliable relief 8

84% of 213 mild/moderate bleeding events achieved sustained bleed control after just one dose of SEVENFACT 225†8

†225 μg/kg initial dose regimen in the clinical trial.

Dose to achieve your treatment goals for mild/moderate bleeds1

SEVENFACT 225: Starting dose of 225 μg/kg, followed, if necessary, 9 hours later by a 75 μg/kg dose every 3 hours until bleed control or 24-hour timepoint‡

‡Consider alternative treatments if successful control of bleeding does not occur within 24 hours of the first administration of SEVENFACT

References:

  1. SEVENFACT [Prescribing Information]. HEMA Biologics; 2022.
  2. NovoSeven [Prescribing Information]. Novo Nordisk; 2022.
  3. Biron-Andreani C, Schved J-F. Eptacog beta: a novel recombinant human factor VIIa for the treatment of hemophilia A and B with inhibitors. Expert Rev Hematol. 2019;12(1):21-28.
  4. Salaj PO, Brabec P, Penka M, et al. Effect of rFVIIa dose and time to treatment on patients with haemophilia and inhibitors: analysis of HemoRec registry data from the Czech Republic. Haemophilia. 2009;15:752-759.
  5. Kavakli K, Yesilipek A, Antmen B, et al. The value of early treatment in patients with haemophilia and inhibitors. Haemophilia. 2010;16:487-494.
  6. Morfini M. Rapid rFVIIa enhanced on-demand dosing in haemophilia inhibitor patients. Eur J Haematol. 2016;96:111-118.
  7. Gomez K, Klamroth R, Mahlangu J, et al. Key issues in inhibitor management in patients with haemophilia. Blood Transfus. 2014;12(suppl1):s319-s329.
  8. Data on file. HEMA Biologics.